No Data
Zhejiang Pharmaceutical: Zhejiang Pharmaceutical 2024 Annual Results Pre-Increase Announcement
Zhejiang Pharmaceutical 2024 Annual Results Advance Notice
Zhejiang Medicine (600216.SH): Expected net income in 2024 to increase by 141.83%-190.01% year-on-year.
Gelonghui, January 22丨Zhejiang Medicine (600216.SH) announced that, according to preliminary calculations by the financial department, it is expected that in 2024, the annual net income attributable to the parent company's owners will be 1,039 million yuan - -1246 million yuan, representing an increase of 609.3604 million yuan - -816.3604 million yuan compared to the same period last year, a year-on-year increase of 141.83% - 190.01%. It is expected that the annual net income attributable to the parent company's owners, after deducting non-recurring gains and losses, will be 1,040 million yuan - 124,800.00.
Is Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Recent Price Movement Underpinned By Its Weak Fundamentals?
Zhejiang Medicine (SHSE:600216) Shareholders YoY Returns Are Lagging the Company's 181% One-year Earnings Growth
zhejiang medicine (600216.SH): folic acid is not included in the main products.
Gelonghui November 22nd, zhejiang medicine (600216.SH) stated on the investor interaction platform that folic acid is not included in the company's main products.
The Three-year Shareholder Returns and Company Earnings Persist Lower as Zhejiang Medicine (SHSE:600216) Stock Falls a Further 4.0% in Past Week
